Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics has initiated a Phase Ib clinical trial of SGN-40 in combination with Rituxan and Gemzar for patients with relapsed or refractory diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma.
Subscribe to our email newsletter
The Phase Ib, open-label single-arm study will enroll up to approximately 30 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) at multiple cancer centers in the US. Patients will receive escalating doses of SGN-40 in combination with Rituxan and Gemzar. The study will assess safety, pharmacokinetics and preliminary antitumor activity of the combination regimen.
Thomas Reynolds, chief medical officer of Seattle Genetics, said: “The SGN-40 plus Rituxan and Gemzar combination trial complements our other ongoing DLBCL trials, including a Phase IIb trial evaluating SGN-40 in combination with Rituxan plus chemotherapy in the second-line setting and a single-agent Phase II trial in relapsed or refractory patients.”